| Literature DB >> 24847360 |
Oscar Acosta1, Luis Solano2, Jorge Escobar3, Miguel Fernandez4, Carlos Solano2, Ricardo Fujita5.
Abstract
Carrion's disease (CD), is a human bartonellosis, that is, endemic in the Andes of Peru, Ecuador, and Colombia. Bartonella bacilliformis, a native hemotrophic bacteria, is the causative agent of CD, and the interaction with the host could have produced changes in the gene frequencies of erythrocyte antigens. The goal here is to investigate the relationship between allele frequencies of blood group systems MNS, Diego, and Duffy and the clinical phases of CD, within a genetic context. In this associative and analytical study, 76 individuals from Bagua Grande, the province of Utcubamba, and the department of Amazonas in Peru, were enrolled. Forty of them resided in Tomocho-Collicate-Vista Hermosa area (high prevalence of cases in chronic phase, verrucous, or eruptive phase, without previous acute phase). Thirty-six individuals were from the area of Miraflores (high prevalence of cases in acute phase only) and were evaluated for blood group systems MNS, Diego, and Duffy. This study constitutes one of the first attempts at evaluating the genetic factors and clinical phases of CD. No significant statistical differences (P > 0.05) between allele frequencies of blood groups MNS, Diego, and Duffy and the prevalence of chronic and acute phases were detected in the two areas of Amazonas, Peru.Entities:
Year: 2014 PMID: 24847360 PMCID: PMC4009165 DOI: 10.1155/2014/576107
Source DB: PubMed Journal: Interdiscip Perspect Infect Dis ISSN: 1687-708X
Figure 1Blood smear of patient in acute phase. Parasitized erythrocytes by bacillary and coccoid forms of B. bacilliformis (arrows), a nucleated erythrocyte (NE), and a band neutrophil (BN) can be observed. Giemsa stain, 1000x.
Figure 2Location of the sampled areas in Bagua Grande (red spot), province of Utcubamba, department of Amazonas, Peru. At left top, map of Peru with location of department (filled in red).
General data and clinical phases of the samples analyzed in this study.
| Characteristics | Tomocho-Collicate-Vista Hermosa | Miraflores |
|---|---|---|
|
|
| |
| Sample | 40 | 36 |
| Sex | ||
| Male | 17 (42.5) | 14 (38.9) |
| Female | 23 (57.5) | 22 (61.1) |
| Total |
|
|
| Age | ||
|
| 23.5 ± 10.6 | 29.5 ± 22.9 |
| Clinical phases* | ||
| Acute phase only | 1a | 12 |
| Chronic phase only | 22 | 0 |
| Acute and chronic phases | 0 | 1b |
| No reported disease or healthy | 17 | 23 |
| Total |
|
|
| Total for analysis |
|
|
X ± SD is the mean ± standard deviation.
*Clinical phases' data of each individual were obtained by self-report (personal interviews) and/or review of clinical records for verification of treatment or supervision of the Carrion's disease.
aOne individual had acute phase and was removed from the analysis “blood group versus clinical phase” in Tomocho-Collicate-Vista Hermosa area, reducing our sample from 40 to 39 individuals.
bOne individual had acute and chronic phases and was removed from the analysis “blood group versus clinical phase” in Miraflores area, reducing our sample from 36 to 35 individuals.
Distribution of blood group systems by area, Bagua, Amazonas, Perú.
| Group | Phenotypes | Tomocho-Collicate-Vista Hermosa | Miraflores |
|
| ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
| Phenotype frequency | Allele | Allele frequency |
| Phenotype frequency | Allele | Allele frequency | ||||
| MN | MM | 15 | 0.375 | M | 0.6625 | 18 | 0.500 | M | 0.6945 | 0.232 | 0.674 |
| MN | 23 | 0.575 | N | 0.3375 | 14 | 0.389 | N | 0.3055 | |||
| NN | 2 | 0.050 | 4 | 0.111 | |||||||
|
| |||||||||||
| Ss | SS | 10 | 0.250 | S | 0.5625 | 10 | 0.278 | S | 0.5835 | 0.955 | 0.796 |
| Ss | 25 | 0.625 | s | 0.4375 | 22 | 0.611 | s | 0.4165 | |||
| Ss | 5 | 0.125 | 4 | 0.111 | |||||||
|
| |||||||||||
| Diego | Di (a+) | 6 | 0.150 | Di a | 0.0750 | 7 | 0.194 | Di a | 0.0972 | 0.607 | 0.625 |
| Di (a−) | 34 | 0.850 | No Di a | 0.9250 | 29 | 0.806 | No Di a | 0.9027 | |||
|
| |||||||||||
| Duffy | Fy (a+b−) | 14 | 0.350 | Fy a | 0.5750 | 13 | 0.361 | Fy a | 0.5695 | 0.952 | 0.945 |
| Fy (a+ b+) | 18 | 0.450 | Fy b | 0.4250 | 15 | 0.417 | Fy b | 0.4305 | |||
| Fy (a− b+) | 8 | 0.200 | 8 | 0.222 | |||||||
| Fy (a− b−) | 0 | 0.000 | 0 | 0.000 | |||||||
Phenotype frequencies (in this case also genotype) of MN blood group system, the most variable, are in Hardy-Weinberg equilibrium (P > 0.05, Chi-square test). In the comparisons of phenotypes and allele frequencies of blood group systems, no significant statistical differences (P > 0.05, Chi-square or Fisher's exact tests) were found between the two areas.
Phenotypes and allele frequencies of blood group systems according clinical phases by area study, Bagua, Amazonas, Peru.
| Group | Area |
| ||||||
|---|---|---|---|---|---|---|---|---|
| Tomocho-Collicate-Vista Hermosa ( | Miraflores | |||||||
| Cases in chronic phase only ( | No reported disease |
| Cases in acute phase only ( | No reported disease |
| |||
| MN | MM | 8 | 7 | 0.759 | 5 | 12 | 0.555 | 0.761 |
| MN | 12 | 10 | 6 | 8 | ||||
| NN | 2 | 0 | 1 | 3 | ||||
| M | 28 (0.6364) | 24 (0.7059) | 0.518 | 16 (0.6667) | 32 (0.6957) | 0.804 | 0.803 | |
| N | 16 (0.3636) | 10 (0.2941) | 8 (0.3333) | 14 (0.3043) | ||||
|
| ||||||||
| Ss | SS | 6 | 4 | 0.791 | 3 | 6 | 0.944 | 0.886 |
| Ss | 14 | 10 | 8 | 14 | ||||
| ss | 2 | 3 | 1 | 3 | ||||
| S | 26 (0.5910) | 18 (0.5294) | 0.587 | 14 (05834) | 26 (0.5653) | 0.884 | 0.952 | |
| s | 18 (0.4090) | 16 (0.4706) | 10 (0.4166) | 20 (0.4347) | ||||
|
| ||||||||
| Diego | Di (a+) | 4 | 2 | 0.679 | 2 | 5 | 1.000 | 1.000 |
| Di (a−) | 18 | 15 | 10 | 18 | ||||
| Di a | 4 (0.0909) | 2 (0.0588) | 0.691 | 2 (0.0833) | 5 (0.1086) | 1.000 | 1.000 | |
| No Di a | 40 (0.9091) | 32 (0.9412) | 22 (0.9167) | 41 (0.8914) | ||||
|
| ||||||||
| Duffy | Fy (a+ b−) | 8 | 6 | 0.945 | 4 | 9 | 0.736 | 0.850 |
| Fy (a+ b+) | 9 | 8 | 6 | 9 | ||||
| Fy (a− b+) | 5 | 3 | 2 | 5 | ||||
| Fy (a− b−) | 0 | 0 | 0 | 0 | ||||
| Fy a | 25 (0.5692) | 20 (0.5883) | 0.859 | 14 (0.5334) | 27 (0.5870) | 0.977 | 0.904 | |
| Fy b | 19 (0.4318) | 14 (04117) | 10 (0.4166) | 19 (0.4130) | ||||
*One individual of the Tomocho-Collicate-Vista Hermosa had acute phase and was removed from this analysis, reducing our sample from 40 to 39 individuals. In a similar way, one individual from Miraflores presented chronic phase and was also removed from the analysis, reducing the number from 36 to 35 individuals.
aIn the comparisons of phenotypes and allele frequencies, considering clinical phases and healthy individuals (2 × 2 clusters), no significant statistical differences (P > 0.05, Chi-square or Fisher's exact tests) were found in each area.
bIn the comparisons of phenotypes and allele frequencies, considering only clinical phases (2 × 2 clusters), no significant statistical differences (P > 0.05, Chi-square or Fisher's exact tests) were found between the two areas.